Biotechnology

As its leaders vie for a top entrepreneurial award, a look at how GenScript quietly became an indispensable engine for global scientific breakthroughs.

A new AI-powered skin patch test for psoriasis just got a major US approval, promising to end costly trial-and-error treatments for millions of patients.

A breakthrough review validates harnessing neutrophils, the immune system's foot soldiers, for cancer, with a new therapy now heading to human trials.

New TempLock™ tech in the SherpaPak® system aims to keep donor hearts stable longer, potentially expanding the reach of life-saving transplants.

A new peer-reviewed study shows MECART cleanrooms cut emissions by 33%, challenging industry standards with verifiable data and a circular design.

LifeSci Advisors' hire of finance and IR veteran Matthew Osborne signals a strategic push amid a competitive market and a rebounding biotech IPO landscape.

A novel gene therapy using precision-guided vectors could offer a one-time treatment for wet AMD, a leading cause of blindness, freeing patients from injections.

For the 5th straight year, WA's life sciences outpace job growth. See how AI leadership and strategic investment fuel its $43.4B economic impact.

Hundreds of lupus advocates descended on Washington, demanding policy reform and research funding, and their persistent efforts are already yielding major results.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

Forge Biologics is one of few CDMOs globally to earn top sustainability honors, signaling a major shift toward greener practices in the biopharma industry.

A new state-of-the-art facility in Chicago aims to secure life-saving medicines, as GEODIS enters a heated race for pharmaceutical logistics dominance.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

A new imaging tool eliminates background noise, offering a revolutionary, high-definition view into the cellular processes that drive life and disease.

A new powerhouse residency program backed by Silicon Valley elite launches near Stanford to turn academic science into fundable healthcare companies.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

Remix Therapeutics' first-in-class drug REM-422 targets a rare cancer at its genetic source, with pivotal data set for a major oncology conference.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.